Catalog No.
DHD71901
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
KLRC1, NKG2-A/NKG2-B type II integral membrane protein, NKG2-A/B-activating NK receptor, CD159 antigen-like family member A, CD159a, NK cell receptor A, NKG2A
Concentration
6.65 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P26715
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
IPH-2201, NN-8765, NNC-0141-0000-0100, NNC-141-01000, monolizumab,anti-NKG2A, humZ270, CAS: 1228763-95-8
Clone ID
Monalizumab
Monalizumab: inhibiting the novel immune checkpoint NKG2A, PMID: 31623687
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells, PMID: 30503213
The NKG2A-HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment, PMID: 32409305
Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, PMID: 32967162
Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221, PMID: 31308062
Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents, PMID: 32344314
Quantitative modeling predicts competitive advantages of a next generation anti-NKG2A monoclonal antibody over monalizumab for the treatment of cancer, PMID: 33501768
[New frontiers in the fight against cancer], PMID: 30973133
Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia, PMID: 27853650
Born to Kill: NK Cells Go to War against Cancer, PMID: 30898260
High-Density of FcγRIIIA + (CD16 +) Tumor-Associated Neutrophils in Metastases Improves the Therapeutic Response of Cetuximab in Metastatic Colorectal Cancer Patients, Independently of the HLA-E/CD94-NKG2A Axis, PMID: 34211852
Targeting NKG2A to elucidate natural killer cell ontogenesis and to develop novel immune-therapeutic strategies in cancer therapy, PMID: 30645023
For research use only. Not for human or drug use.
